Which Tyrosine Kinase Inhibitor we must Apply before?: A Case Report of Crizotinib-Resistant Patient with Concomitant EGFR and EML4-ALK Gene Mutations
Makaleler > Tam Makale · 2016
Yazarlar: S Cokmert, Ali VERAL, N Akyurek, SD Kececi, O Sivrikoz, E Yilmaz, O Tanriverdi, U Coskun
West Indian Medical Journal, Uluslararası, Wos, 2016
Özet
The concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocations in lung adenocancers are very rare scenarios. Until now, 42 cases described in the literature have all been treated by different drugs. There is no overall consensus regarding the treatment for this adenocarcinoma subgroup. We report here a case of lung